Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48891 | 0.88 | EGLN1 (0.37) | EGLN1ADRA1A | |
| SCHEMBL2487654 | 0.88 | EGLN1 (0.39) | PRMT1EPHX2EGLN1ADRA1A | |
| SCHEMBL254189 | 0.84 | EPHX1 (0.46) | PRMT1EPHX2EPHX1 | |
| SCHEMBL17133211 | 0.81 | EPHX1 (0.50) | EPHX2EPHX1 | |
| SCHEMBL14519143 | 0.80 | EPHX1 (0.39) | PRMT1EPHX2EPHX1 | |
| SCHEMBL19838191 | 0.79 | EPHX1 (0.50) | PRMT1EPHX2EPHX1 | |
| SCHEMBL10481520 | 0.78 | EPHX1 (0.58) | EPHX2EPHX1 | |
| SCHEMBL139047 | 0.78 | TSHR (0.42) | PRMT1ADRA1A | |
| SCHEMBL2616751 | 0.78 | TSHR (0.46) | EPHX2EGLN1ADRA1A | |
| SCHEMBL10557593 | 0.78 | EPHX1 (0.57) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379118-B1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GEN ELECTRIC (US) | 2017-10-18 | — | — | EP | claimed |
| US-20140147387-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2014-05-29 | — | — | US | claimed |
| US-8728529-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2014-05-20 | — | — | US | claimed |
| US-8574549-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2013-11-05 | — | — | US | claimed |
| US-20100166664-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | claimed |
| US-20100166665-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | claimed |
| CN-107029250-B | Nanoparticle contrast agents for diagnostic imaging | 通用电气健康护理有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-2379118-B1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GEN ELECTRIC (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2379118-B1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GEN ELECTRIC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9585974-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585974-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160296641-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GE HEALTHCARE LIMITED (GB) | 2016-10-13 | — | — | US | disclosed |
| US-20160296641-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GE HEALTHCARE LIMITED (GB) | 2016-10-13 | — | — | US | disclosed |
| US-8574549-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-8574549-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2379118-A2 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | General Electric Company (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010076237-A2 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100166666-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100166664-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100166665-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296641-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | CD47, CD63, MACO1 | PRMT1 1550/4885EPHX2 3244/4885EPHX1 2499/4885 |
| US-20140147387-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | CD47, CD63, MACO1 | PRMT1 1550/4885EPHX2 3244/4885EPHX1 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.